Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α

Zheng (David) Qian, Sushant K. Kachhap, Spencer J. Collis, Henk M W Verheul, Michael A. Carducci, Peter Atadja, Roberto Pili

Research output: Contribution to journalArticle

237 Citations (Scopus)

Abstract

Hypoxia-inducible factor 1α (HIF-1α) plays a critical role in transcriptional gene activation involved in tumor angiogenesis. A novel class of agents, the histone deacetylase (HDAC) inhibitors, has been shown to inhibit tumor angiogenesis and HIF-1α protein expression. However, the molecular mechanism responsible for this inhibition remains to be elucidated. In the current study, we investigated the molecular link between HIF-1α inhibition and HDAC inhibition. Treatment of the VHL-deficient human renal cell carcinoma cell line UMRC2 with the hydroxamic HDAC inhibitor LAQ824 resulted in a dose-dependent inhibition of HIF-1α. protein via a VHL-independent mechanism and reduction of HIF-1α transcriptional activity. HIF-1α inhibition by LAQ824 was associated with HIF-1α acetylation and polyubiquitination. HIF-1α immunoprecipitates contained HDAC activity. Then, we tested different classes of HDAC inhibitors with diverse inhibitory activity of class I versus class II HDACs and assessed their capability of targeting HIF-1α. Hydroxamic acid derivatives with known activity against both class I and class II HDACs were effective in inhibiting HIF-1α at low nanomolar concentrations. In contrast, valproic acid and trapoxin were able to inhibit HIF-1α only at concentrations that are effective against class II HDACs. Coimmunoprecipitation studies showed that class II HDAC4 and HDAC6 were associated with HIF-1α protein. Inhibition by small interfering RNA of HDAC4 and HDAC6 reduced HIF-1α protein expression and transcriptional activity. Taken together, these results suggest that class II HDACs are associated with HIF-1α stability and provide a rationale for targeting HIF-1α with HDAC inhibitors against class II isozymes.

Original languageEnglish (US)
Pages (from-to)8814-8821
Number of pages8
JournalCancer Research
Volume66
Issue number17
DOIs
StatePublished - Sep 1 2006
Externally publishedYes

Fingerprint

Hypoxia-Inducible Factor 1
Histone Deacetylases
Histone Deacetylase Inhibitors
Transcriptional Activation
Proteins
Hydroxamic Acids
Valproic Acid
Acetylation
Renal Cell Carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Qian, Z. D., Kachhap, S. K., Collis, S. J., Verheul, H. M. W., Carducci, M. A., Atadja, P., & Pili, R. (2006). Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α. Cancer Research, 66(17), 8814-8821. https://doi.org/10.1158/0008-5472.CAN-05-4598

Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α. / Qian, Zheng (David); Kachhap, Sushant K.; Collis, Spencer J.; Verheul, Henk M W; Carducci, Michael A.; Atadja, Peter; Pili, Roberto.

In: Cancer Research, Vol. 66, No. 17, 01.09.2006, p. 8814-8821.

Research output: Contribution to journalArticle

Qian, ZD, Kachhap, SK, Collis, SJ, Verheul, HMW, Carducci, MA, Atadja, P & Pili, R 2006, 'Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α', Cancer Research, vol. 66, no. 17, pp. 8814-8821. https://doi.org/10.1158/0008-5472.CAN-05-4598
Qian, Zheng (David) ; Kachhap, Sushant K. ; Collis, Spencer J. ; Verheul, Henk M W ; Carducci, Michael A. ; Atadja, Peter ; Pili, Roberto. / Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α. In: Cancer Research. 2006 ; Vol. 66, No. 17. pp. 8814-8821.
@article{68b1e3218fed48ada3f0f55de6193824,
title = "Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α",
abstract = "Hypoxia-inducible factor 1α (HIF-1α) plays a critical role in transcriptional gene activation involved in tumor angiogenesis. A novel class of agents, the histone deacetylase (HDAC) inhibitors, has been shown to inhibit tumor angiogenesis and HIF-1α protein expression. However, the molecular mechanism responsible for this inhibition remains to be elucidated. In the current study, we investigated the molecular link between HIF-1α inhibition and HDAC inhibition. Treatment of the VHL-deficient human renal cell carcinoma cell line UMRC2 with the hydroxamic HDAC inhibitor LAQ824 resulted in a dose-dependent inhibition of HIF-1α. protein via a VHL-independent mechanism and reduction of HIF-1α transcriptional activity. HIF-1α inhibition by LAQ824 was associated with HIF-1α acetylation and polyubiquitination. HIF-1α immunoprecipitates contained HDAC activity. Then, we tested different classes of HDAC inhibitors with diverse inhibitory activity of class I versus class II HDACs and assessed their capability of targeting HIF-1α. Hydroxamic acid derivatives with known activity against both class I and class II HDACs were effective in inhibiting HIF-1α at low nanomolar concentrations. In contrast, valproic acid and trapoxin were able to inhibit HIF-1α only at concentrations that are effective against class II HDACs. Coimmunoprecipitation studies showed that class II HDAC4 and HDAC6 were associated with HIF-1α protein. Inhibition by small interfering RNA of HDAC4 and HDAC6 reduced HIF-1α protein expression and transcriptional activity. Taken together, these results suggest that class II HDACs are associated with HIF-1α stability and provide a rationale for targeting HIF-1α with HDAC inhibitors against class II isozymes.",
author = "Qian, {Zheng (David)} and Kachhap, {Sushant K.} and Collis, {Spencer J.} and Verheul, {Henk M W} and Carducci, {Michael A.} and Peter Atadja and Roberto Pili",
year = "2006",
month = "9",
day = "1",
doi = "10.1158/0008-5472.CAN-05-4598",
language = "English (US)",
volume = "66",
pages = "8814--8821",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α

AU - Qian, Zheng (David)

AU - Kachhap, Sushant K.

AU - Collis, Spencer J.

AU - Verheul, Henk M W

AU - Carducci, Michael A.

AU - Atadja, Peter

AU - Pili, Roberto

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Hypoxia-inducible factor 1α (HIF-1α) plays a critical role in transcriptional gene activation involved in tumor angiogenesis. A novel class of agents, the histone deacetylase (HDAC) inhibitors, has been shown to inhibit tumor angiogenesis and HIF-1α protein expression. However, the molecular mechanism responsible for this inhibition remains to be elucidated. In the current study, we investigated the molecular link between HIF-1α inhibition and HDAC inhibition. Treatment of the VHL-deficient human renal cell carcinoma cell line UMRC2 with the hydroxamic HDAC inhibitor LAQ824 resulted in a dose-dependent inhibition of HIF-1α. protein via a VHL-independent mechanism and reduction of HIF-1α transcriptional activity. HIF-1α inhibition by LAQ824 was associated with HIF-1α acetylation and polyubiquitination. HIF-1α immunoprecipitates contained HDAC activity. Then, we tested different classes of HDAC inhibitors with diverse inhibitory activity of class I versus class II HDACs and assessed their capability of targeting HIF-1α. Hydroxamic acid derivatives with known activity against both class I and class II HDACs were effective in inhibiting HIF-1α at low nanomolar concentrations. In contrast, valproic acid and trapoxin were able to inhibit HIF-1α only at concentrations that are effective against class II HDACs. Coimmunoprecipitation studies showed that class II HDAC4 and HDAC6 were associated with HIF-1α protein. Inhibition by small interfering RNA of HDAC4 and HDAC6 reduced HIF-1α protein expression and transcriptional activity. Taken together, these results suggest that class II HDACs are associated with HIF-1α stability and provide a rationale for targeting HIF-1α with HDAC inhibitors against class II isozymes.

AB - Hypoxia-inducible factor 1α (HIF-1α) plays a critical role in transcriptional gene activation involved in tumor angiogenesis. A novel class of agents, the histone deacetylase (HDAC) inhibitors, has been shown to inhibit tumor angiogenesis and HIF-1α protein expression. However, the molecular mechanism responsible for this inhibition remains to be elucidated. In the current study, we investigated the molecular link between HIF-1α inhibition and HDAC inhibition. Treatment of the VHL-deficient human renal cell carcinoma cell line UMRC2 with the hydroxamic HDAC inhibitor LAQ824 resulted in a dose-dependent inhibition of HIF-1α. protein via a VHL-independent mechanism and reduction of HIF-1α transcriptional activity. HIF-1α inhibition by LAQ824 was associated with HIF-1α acetylation and polyubiquitination. HIF-1α immunoprecipitates contained HDAC activity. Then, we tested different classes of HDAC inhibitors with diverse inhibitory activity of class I versus class II HDACs and assessed their capability of targeting HIF-1α. Hydroxamic acid derivatives with known activity against both class I and class II HDACs were effective in inhibiting HIF-1α at low nanomolar concentrations. In contrast, valproic acid and trapoxin were able to inhibit HIF-1α only at concentrations that are effective against class II HDACs. Coimmunoprecipitation studies showed that class II HDAC4 and HDAC6 were associated with HIF-1α protein. Inhibition by small interfering RNA of HDAC4 and HDAC6 reduced HIF-1α protein expression and transcriptional activity. Taken together, these results suggest that class II HDACs are associated with HIF-1α stability and provide a rationale for targeting HIF-1α with HDAC inhibitors against class II isozymes.

UR - http://www.scopus.com/inward/record.url?scp=33749006252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749006252&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-4598

DO - 10.1158/0008-5472.CAN-05-4598

M3 - Article

C2 - 16951198

AN - SCOPUS:33749006252

VL - 66

SP - 8814

EP - 8821

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 17

ER -